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ABSTRACT
Objective To compare differences in cardiovascular
(CV) risk factors assessment and management among
patients with rheumatoid arthritis (RA) and inﬂammatory
bowel disease (IBD) with that of matched controls.
Methods A matched cohort study was conducted
using primary care electronic health records for one
London borough. All patients diagnosed with RA or IBD,
and matched controls registered with local general
practices on 12th of January 2014 were identiﬁed. The
study compared assessment and treatment of CV risk
factors (blood pressure, body mass index, cholesterol and
smoking) in the year before, the year after, and 5 years
after RA and IBD diagnosis.
Results A total of 1121 patients with RA and 1875
patients with IBD were identiﬁed and matched with
4282 and, respectively, 7803 controls. Patients with RA
were 25% (incidence rate ratio, 1.25, 95% CI 1.12 to
1.35) more likely to have a CV risk factor measured
compared with matched controls. The difference declined
to 8% (1.08, 1.04 to 1.14) over 5 years of follow-up.
The corresponding ﬁgures for IBD were 26% (1.26, 1.16
to 1.38) and 10% (1.10, 1.05 to 1.15). Patients with
RA showed higher antihypertensive prescription rates
during 5 years of follow-up (OR, 1.37, 95% CI 1.14 to
1.65) and patients with IBD showed higher statin
prescription rates in the year preceding diagnosis (2.30,
1.20 to 4.42). Incomplete CV risk assessment meant
that QRISK scores could be calculated for less than a
ﬁfth (17%) and clinical recording of CV disease (CVD)
risk scores among patients with RA and IBD was 11%
and 6%, respectively.
Conclusions The assessment and treatment of vascular
risk in patients with RA and IBD in primary care is
suboptimal, particularly with reference to CVD risk score
calculation.
Chronic inﬂammatory disorders are increasingly
acknowledged to be associated with heightened risk
of cardiovascular disease (CVD) comorbidity, the
leading cause of death worldwide.1–5 A recent
study with primary care data documented increased
risk of stroke, type 2 diabetes and coronary heart
disease among several inﬂammatory disorders,
including rheumatoid arthritis (RA) and ulcerative
colitis.5 The increasing recognition for heightened
CVD risk among chronic inﬂammatory patients has
led to the development of clinical recommenda-
tions to facilitate the prevention of inﬂammation-
related CVD risk. These guidelines recommend the
screening of inﬂammatory patients for vascular risk
factors including blood pressure (BP), cholesterol,
smoking, body mass index (BMI) and the use of a
validated CVD risk score to predict CVD risk.6
The extent to which these recommendations are
implemented into routine care is, however, poorly
understood. Earlier evidence from rheumatology
clinic settings suggested deﬁcient vascular risk
assessment practices.7–9 This evidence is less avail-
able within a primary care context—the main
setting for CVD risk assessment and treatment in
the UK. Recently, Alemao et al10 found no differ-
ences in the assessment and treatment of CV risk
factors among patients with RA in a large primary
care database. The extent to which national recom-
mendations are implemented at a more local level
or across different inﬂammatory disorders is less
explored. The main aim of the present study was
to identify the extent to which primary care pra-
ctitioners from one of the most deprived and
ethnically diverse areas of the UK implemented
recommended guidelines for CV risk factors assess-
ment and treatment among patients with RA and
inﬂammatory bowel disease (IBD).
METHODS
Data
The data for the present study were based on the
Lambeth DataNet, a patient-level primary care
database containing electronic health records data
for over 350 000 patients living in one London
borough (Lambeth), including their demographics,
clinical diagnoses, specialist services referral,
laboratory tests and treatment. Lambeth is among
the most ethnically diverse borough in the UK and
the ninth most deprived borough in London, with
36.7% of its population living in the most deprived
lower super output areas (LSOAs) in England. The
study population was selected using Read medical
codes and included all patients diagnosed with RA
or IBD (including ulcerative colitis and Crohn’s
disease) after current registration date (the date
when the patient was registered uninterruptedly
with the practice). Patients with a diagnosis of the
selected disorders were matched on age, gender
and general practice with up to four controls ran-
domly sampled from all patients who were disease-
free. The controls were also required to be regis-
tered at the case index date. The index date for
controls was determined as the closest observation
to the case index date.
Study measurements
The management of traditional CV risk factors and
CVD risk score was evaluated as the percentage of
patients screened for at each CV risk factor and the
percentage of patients prescribed antihypertensive
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and lipid-lowering therapies at three different time points: the
12 months before the RA and IBD index date, the 12 months
following the index date, and within 5 years following the index
date. The study also evaluated the percentage of patients mea-
sured for three or four, as well as for all four CV risk factors at
the speciﬁed time periods. We also calculated the proportion of
patients that were hypertensive (systolic blood pressure (SBP)/
diastolic blood pressure ≥140/90 mm Hg, or were on the hyper-
tension register), hypercholesterolemic (total cholesterol
≥5 mmol/L), obese (BMI>29) or current smokers at the speci-
ﬁed time points. Additionally, we estimated the percentage of
patients with a recorded CVD risk score, as well as the percent-
age of patients with available data to calculate a QRISK score—
a prediction algorithm to assess CVD risk based on the
QRESEARCH database.11 BP, total cholesterol, BMI and
smoking data from medical records were analysed in patients
with RA/IBD and their matched controls. CVD risk assessment
was deﬁned as the recording of a CV risk score (including
Framingham Risk Score, Joint British Societies risk score,
QRISK score). All CV risk factors and relevant therapies were
operationalised as binary variables—yes (1) if the risk factor was
measured and no (0) if the risk factor was not recorded during
the speciﬁed time points.
Covariates
Several covariates measured at baseline were considered includ-
ing patients’ gender (male/females) and age at index date (the
case index was used for matched controls). Ethnicity was self-
reported by patients, and classiﬁed patients into White, Black,
Asian, Mixed and Other. Ethnicity was categorised as missing if
recorded as refused or not recorded. Deprivation was assessed
by mapping patient postcodes to the lower super output area
(LSOA) and assigning the index of multiple deprivation (IMD
07) score for that area. Scores were then grouped into ﬁve quin-
tiles, from most to least deprived. The study also considered
baseline differences between patients with RA and IBD and
their matched controls with respect to diabetes, cancer, CVDs
(eg, stroke, angina, myocardial infarction), depression and
chronic kidney disease.
Statistical analysis
Baseline characteristics between patients with RA and IBD and
their matched controls were compared using descriptive statis-
tics. Differences in the assessment of traditional CV risk factors
and relevant treatment were compared between patients with
RA and IBD with their matched controls without accounting for
matching. These comparisons were calculated for the 12 months
before, the 12 months following, as well as within 5 years from
the case index date. Graphics were used to illustrate changes
over time in the percentage of patients with measurements for
traditional CV risk factors from 12 months before baseline to
5 years after the case index date. Conditional Poisson regression
analysis was used to estimate differences cases and controls in
the number of traditional CV risk factors assessed at the three
speciﬁed time points. Conditional logistic regression was used
to estimate differences in individual CV risk factors assessment
and treatment at the prespeciﬁed time points. These analyses
adjusted for age, gender, ethnicity and deprivation. Mixed-
effects regression was used to estimate change over time in CV
risk factors recording. Continuous QRISK scores were calcu-
lated and categorised into percentiles of 0%–10%, 10%–20%
and >20%. All statistical analyses were performed using STATA
V.14. An α level of 0.05 was used as the criterion for statistical
signiﬁcance.
RESULTS
The study identiﬁed 1121 patients diagnosed with RA who were
matched with 4282 controls, and 1875 patients diagnosed with
IBD and matched with 7308 controls (table 1). Among the
patients with RA, 77% were female and had a mean age at RA
diagnosis of 54 years. Among patients with IBD, 50% were
female and the mean age at IBD diagnosis was 38 years. With
respect to ethnicity, over a third were of white ethnic origins,
about a sixth were of mixed ethnic origins and about a tenth
of black origins. Just over 80% of both cases and controls were
in the two most deprived quintiles. There were no major dif-
ferences between cases and their matched controls with regard
to chronic illnesses at baseline, with the exception of cancer,
which was twice as common among RA matched controls (9%)
compared with RA cases (4%). Overall, patients with RA had
higher rates of chronic illnesses compared with patients
with IBD.
Figure 1 illustrates the cumulative trends in CV risk factor
recording from the 12 months before the case index date and
up to 5 years following the case index date. There was no appar-
ent change in the percentage of patients with RA or IBD with
CV risk factors measured from the 12 months before to the
12 months after the index date. Cumulatively, the percentage of
patients with IBD and RA with CV risk factors assessed
Table 1 Characteristics of study participants at baseline
RA
patients
(N=1121)
RA
controls
(N=4282)
IBD
patients
(N=1875)
IBD
controls
(N=7308)
Females 939 (77) 3741 (77) 943 (50%) 3677 (50%)
Age at diagnosis—
mean (SD)
54 (15) 54 (15) 38 (19) 38 (19)
Ethnicity
White 423 (35) 1677 (35) 780 (42) 2458 (33)
Black 165 (14) 732 (15) 181 (10) 1046 (15)
Asian 92 (8) 285 (6) 85 (4) 392 (5)
Mixed 233 (19) 870 (18) 446 (24) 1299 (18)
Other 158 (13) 539 (11) 99 (5) 565 (8)
Missing 146 (12) 747 (15) 286 (15) 1548 (21)
IMD quintile
Most 461 (38) 1694 (35) 604 (32) 2505 (34)
Second 556 (46) 2340 (48) 93 6 (50) 3446 (47)
Third 150 (12) 573 (12) 233 (13) 932 (13)
Fourth 26 (2) 132 (3) 60 (3) 212 (3)
Least / 5 (0) / 4 (0.1)
Missing 24 (2) 106 (2) 42 (2) 209 (3)
Chronic kidney
disease
39 (3) 146 (3) 28 (2) 92 (1)
Diabetes 134 (12) 469 (11) 125 (7) 431 (6)
Antihypertensive
drugs*
74 (7) 341 (8) 60 (3) 265 (4)
Lipid-lowering drugs† 26 (2) 88 (2) 21 (1) 57 (1)
Cardiovascular
disease
98 (9) 362 (8) 103 (5) 326 (4)
Depression 163 (15) 651 (15) 205 (11) 860 (12)
Cancer 48 (4) 397 (9) 54 (3) 229 (3)
Figures are frequencies and percentages, unless otherwise specified.
Percentages based on recorded data.
*Percentage of participants prescribed antihypertensive drugs in the year preceding
disease diagnosis.
†Percentage of participants prescribed lipid-lowering drugs in the year preceding
disease diagnosis.
IBD, inflammatory bowel disease; IMD, Index of multiple deprivation; RA, rheumatoid
arthritis.
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increased substantively and was most commonly performed
with regard to SBP and less commonly for BMI. At most a ﬁfth
of patients with RA (20%) and at most a sixth (16%) of patients
with IBD had one CV risk factor measured within the ﬁrst
12 months following the index date. These rates increased at 5
years of follow-up to about half (53%) among patients with RA
and just over a third (39%) among patients with IBD. However,
less than a tenth of patients with RA (8%) or IBD (4%) had all
four CV risk factors recorded during the 5-year follow-up
period. Time-trend analyses for all risk factors were statistically
signiﬁcant (p<0.001). Similar trends but of lower magnitude
were observed among RA and IBD matched controls.
Table 2 illustrates that about a tenth of patients with RA and
IBD had their BP, total cholesterol and BMI recorded during the
12 months following the index date, and that these measure-
ment rates increased about threefold during the 5-year
follow-up period. Notably, only a minority of patients with RA
(3%) and IBD (2%) had their CVD risk score measured within
the 12-month period following RA and IBD index date. These
ﬁgures increased to about 11% (RA) and 6% (IBD) during the
5-year follow-up period. No signiﬁcant differences between
patients with RA or IBD and their matched controls were
revealed with regard to CV risk scoring measurement.
Compared with their matched controls, patients with RA were
more likely to have SBP, smoking and BMI (with the exception
of the 5 years of follow-up) measured following the index date.
Similar ﬁndings emerged among patients with IBD. The propor-
tion of patients with RA who were prescribed antihypertensive
and lipid-lowering therapies at 12-month and 5-year follow-up
period was 10% and 24%, and 5% and 15%, respectively.
These ﬁgures were lower for non-RA matched controls (7% and
9%, and 5% and 13%, respectively). The difference reached
statistical signiﬁcance only with respect to antihypertensive
therapy prescribing over the 5-year follow-up period (OR 1.40,
95% CI 1.12 to 1.75). Patients with IBD presented higher rates
of lipid-lowering therapy (3.21, 1.44 to 7.15) before the index
date, but not post-IBD diagnosis.
Patients with RA were more likely to have hypertension (1.99,
1.20 to 3.28), be classiﬁed as obese (1.64, 1.12 to 2.40) at
12 months of follow-up and be current smokers at all time
points compared with their matched controls. Patients with IBD
presented similar association patterns, with the exception of
BMI where no evidence of signiﬁcant differences in assessment
was evident. The only signiﬁcant differences in diabetes rates
were observed among patients with RA at 12 months of
follow-up (1.42, 1.07 to 1.89).
Conditional Poisson regression analyses (table 3) revealed sig-
niﬁcantly higher rates of CV risk factors measurement across the
three time points among patients with both RA and IBD. For
instance, at 12 months of follow-up, patients with IBD were
26% (incidence rate ratio, 1.26, 95% CI 1.16 to 1.38) more
likely to have one or more CV risk factors measurement com-
pared with their matched controls. Similar association but of
lower magnitude (1.10, 1.05 to 1.15) was observed during the
5-year follow-up period.
DISCUSSION
This study represents one of the few prospective studies on the
assessment and treatment of CV risk factors among an ethnically
diverse and deprived RA and IBD primary care population. The
study compared rates and mean values of CV risk factor as well
as CV treatment in the 12 months before disease diagnosis,
within 12 months from disease diagnosis, and subsequently and
up to 5 years following disease diagnosis. Overall the evidence
implies suboptimal assessment of CVD risk among two of the
most common inﬂammatory disorders. While patients with RA
and IBD were more likely to have CV risk factors measured and
treated compared with their matched controls, this association
occurred in the context of very low rates of CV risk factors
assessment and treatment. Just about a tenth of patients with
RA had all four CV risk factors measured—essential for accurate
estimation of future CVD risk—in the 12 months following
disease diagnosis. The same ﬁgure for patients with IBD stood
at just 6%, documenting important discrepancies within the
same group of disorders. While there was encouraging evidence
for improved rates of CV risk factors measurement and treat-
ment in the long term, our study data enabled the calculation of
a CVD risk score at 5 years of follow-up for about a ﬁfth of
Figure 1 Cumulative trends in recording of vascular risk factors from the year before and up to 5 years following disease diagnosis in patients and
controls. (A) Patients with rheumatoid arthritis. (B) Controls with rheumatoid arthritis. (C) Patients with inﬂammatory bowel disease. (D) Controls
with inﬂammatory bowel disease. BMI, body mass index; RF, risk factors; SBP, systolic blood pressure.
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Table 2 Differences in the percentage of patients and controls with CV risk assessed and treated over time
RA patients RA controls ORs (95% CI)
1 year before 1 year after 5 years after 1 year before 1 year after 5 years after 1 year before 1 year after 5 years after
BP recorded 130 (12) 125 (11) 347 (31) 427 (10) 385 (9) 1188 (28) 1.14 (0.89 to 1.46) 1.50 (1.10 to 1.90) 1.40 (1.15 to 1.70)
Hypertension* 329 (29) 472 (43) 545 (49) 1085 (26) 1130 (26) 1728 (40) 1.07 (0.59 to 1.94) 1.99 (1.20 to 3.28) 1.28 (0.94 to 1.76)
AHT 39 (3) 107 (10) 268 (24) 135 (3) 307 (7) 808 (19) 0.93 (0.60 to 1.47) 1.32 (0.94 to 1.85) 1.40 (1.12 to 1.75)
TC recorded 150 (13) 128 (11) 390 (35) 473 (11) 406 (9) 1253 (29) 1.34 (1.05 to 1.72) 1.15 (0.88 to 1.49) 1.21 (0.98 to 1.48)
High cholesterol† 59 (5) 50 (4) 148 (13) 206 (5) 173 (4) 578 (13) 1.19 (0.83 to 1.69) 0.98 (0.67 to 1.43) 0.83 (0.65 to 1.05)
LLD recorded 18 (2) 55 (5) 167 (15) 55 (1) 203 (5) 556 (13) 1.33 (0.68 to 2.65) 1.02 (0.68 to 1.55) 1.20 (0.93 to 1.55)
Smoking recorded 257 (23) 235 (21) 427 (38) 736 (17) 664 (15) 1346 (32) 1.57 (1.29 to 1.90) 1.44 (1.17 to 1.77) 1.25 (1.05 to 1.50)
Current smoker 149 (13) 127 (11) 205 (18) 341 (8) 317 (7) 591 (14) 1.88 (1.48 to 2.38) 1.69 (1.30 to 2.20) 1.45 (1.17 to 1.80)
BMI recorded 150 (13) 139 (13) 374 (34) 436 (10) 351 (8) 1226 (28) 1.52 (1.19 to 1.93) 1.49 (1.15 to 1.92) 1.21 (0.99 to 1.48)
Obesity‡ 50 (4) 54 (5) 144 (13) 163 (4) 120 (3) 486 (11) 1.38 (0.94 to 2.00) 1.64 (1.12 to 2.40) 1.06 (0.83 to 1.34)
Diabetes mellitus 88 (8) 120 (11) 270 (24) 279 (7) 323 (8) 846 (20) 1.30 (0.94 to 1.80) 1.42 (1.07 to 1.89) 1.22 (0.99 to 1.48)
CVD risk scores§ 31 (3) 28 (2) 121 (11) 144 (3) 143 (3) 479 (11) 0.72 (0.46 to 1.14) 0.79 (0.50 to 1.26) 0.91 (0.70 to 1.18)
QRISK score data¶ 45 (4) 22 (2) 191 (17) 129 (3) 86 (2) 685 (16) 1.42 (0.76 to 2.68) 0.93 (0.84 to 4.46) 1.22 (0.91 to 1.63)
IBD patients IBD controls ORs (95% CI)
1 year before 1 year after 5 years after 1 year before 1 year after 5 years after 1 year before 1 year after 5 years after
BP recorded 248 (13) 234 (12) 520 (28) 716 (10) 620 (8) 1662 (23) 1.36 (1.13 to 1.64) 1.58 (1.30 to 1.91) 1.37 (1.16 to 1.61)
Hypertension 246 (14) 362 (19) 430 (23) 977 (14) 957 (13) 1440 (20) 1.77 (0.96 to 3.24) 2.07 (0.99 to 4.32) 1.30 (0.88 to 1.92)
AHT 32 (4) 77 (7) 213 (11) 112 (2) 287 (4) 730 (10) 1.16 (0.72 to 1.87) 1.12 (0.78 to 1.62) 1.19 (0.94 to 1.49)
TC recorded 206 (11) 177 (10) 549 (29) 672 (10) 648 (9) 2026 (28) 1.27 (1.01 to 1.60) 1.09 (0.86 to 1.39) 1.13 (0.94 to 1.34)
High cholesterol 61 (3) 47 (3) 154 (8) 190 (3) 203 (3) 648 (9) 1.23 (0.88 to 1.74) 0.82 (0.56 to 1.120) 0.79 (0.63 to 0.98)
LLD recorded 16 (1) 47 (3) 142 (8) 26 (0) 175 (2) 440 (7) 3.21 (1.44 to 7.15) 0.98 (0.63 to 1.54) 1.05 (0.80 to 1.36)
Smoking recorded 422 (23) 319 (17) 576 (31) 1113 (15) 903 (13) 1920 (26) 1.49 (1.27 to 1.79) 1.32 (1.11 to 1.57) 1.16 (0.99 to 1.34)
Current smoker 183 (10) 146 (8) 255 (14) 590 (8) 490 (7) 942 (13) 1.17 (0.95 to 1.43) 1.12 (0.89 to 1.40) 0.98 (0.81 to 1.18)
BMI recorded 332 (18) 235 (12) 520 (27) 720 (10) 573 (8) 1606 (22) 2.24 (1.87 to 2.68) 1.61 (1.32 to 1.96) 1.31 (1.12 to 1.53)
Obesity 40 (2) 41 (2) 119 (6) 197 (3) 220 (3) 571 (8) 0.80 (0.54 to 1.18) 0.72 (0.48 to 1.06) 0.77 (0.60 to 0.98)
Diabetes mellitus 73 (4) 115 (6) 255 (14) 245 (3) 365 (5) 883 (12) 1.20 (0.84 to 1.71) 1.28 (0.97 to 1.61) 1.14 (0.94 to 1.39)
CVD risk scores 33 (2) 32 (2) 111 (6) 156 (2) 123 (2) 430 (6) 0.71 (0.46 to 1.10) 0.90 (0.56 to 1.44) 0.90 (0.72 to 1.22)
QRISK score data 123 (11) 35 (2) 142 (17) 514 (12) 162 (2) 542 (16) 0.81 (0.41 to 1.59) 1.47 (0.81 to 2.68) 1.19 (0.90 to 1.56)
Figures are frequencies and percentages, unless otherwise stated.
*Hypertension defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg.
†High cholesterol defined as total cholesterol ≥5.0 mmol/L.
‡Obesity defined as BMI ≥30 kg/m2.
§Risk score recorded by practitioners.
¶QRISK scores in the year before diagnosis defined as between registration and diagnosis.
AHT, antihypertensive drugs; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; IBD, inflammatory bowel disease; LLD, lipid-lowering drugs; RA, rheumatoid arthritis; TC, total cholesterol.
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patients with RA and IBD. When comparing the two inﬂamma-
tory conditions, patients with RA presented higher rates of CV
risk factors measurement and treatment relative to patients with
IBD. This difference may be explained by the availability of
National Institute for Health and Care Excellence recommenda-
tions for CVD risk screening among patients with RA newly
diagnosed, while general recommendations for CVD risk screen-
ing are missing for patients with IBD. Or by the greater avail-
ability of empirical evidence for increased CVD risk among
patients with RA compared with patients with IBD.
Given that primary care practitioners are responsible for CVD
prevention in the general population and the award of ﬁnancial
incentives for complete CV risk monitoring, higher rates of CV
risk factors measurement and treatment were expected. Several
factors may account for the low rates of CV risk factors meas-
urement and treatment observed in this study. Some practi-
tioners may use a medical code denoting hypertension or
obesity without recording the actual value, rendering the infor-
mation of little value when trying to estimate a CVD risk score.
The younger mean age (38 years) at IBD diagnosis means that it
may be uncommon to observe high rates of CV risk factors (ie,
SBP, hypercholesterolaemia) in this age group and thus practi-
tioners may be less likely to screen these patients for the pres-
ence of CV risk factors. Besides, existing CVD risk score,
instruments (eg, Reynolds CVD risk, QRISK II, SCORE) tend to
underestimate future CVD events among patients with RA pos-
sibly disincentivising practitioners from recording CV risk
factors data. Also, since patients with both RA and IBD would
be under the care of a specialist (ie, rheumatologist, gastroenter-
ologist), there may be the expectation that CV risk would also
be assessed in specialist clinics. Future studies that combine data
from both primary and secondary care are needed to validate
this suggestion and also to understand the extent to which CV
risk screening is shared or not among different clinicians. In
addition, methodological shortcomings of the study data (eg,
under-reporting, lower proportion of people over 65 years of
age) may also partially account for the study ﬁndings.
Risk charts used for CVD risk stratiﬁcation in patients with
rheumatic diseases, in particular in those with RA, have proved
to underestimate the actual CVD risk of these patients. It is
especially true for those included in the category of moderate
(intermediate) risk. With respect to this, a cohort study disclosed
that 63% of patients with RA classiﬁed as having moderate
CVD risk according to the SCORE had severe carotid ultra-
sound abnormalities (mainly carotid plaques).12 Therefore,
besides traditional algorithms that should be routinely used in
all cases, additional tools should be considered for CVD risk
assessment of patients with inﬂammatory diseases.12 13
Despite a breadth of evidence as to the association of chronic
inﬂammatory (CI) disorders with increased risk of CVD,5 14
there is limited evidence in the current literature about CV risk
factors assessment and treatment in routine care. Alemao et al10
found no substantial difference in the assessment, treatment and
attainment of CV risk factor goals among a representative
sample of patients with RA and non-RA matched controls.
Similarly, Monk et al15 identiﬁed similar rates of CVD screening
among patients with RA and age-matched, gender-matched and
practice-matched non-RA patients. Our study ﬁndings for sig-
niﬁcant differences in assessment and treatment of CV risk
factors between patients with RA and matched controls imply
that at a more local-level important differences may be
observed. The Lambeth DataNet is a local dataset and it may
have picked up on differences that nationwide datasets10 may
have overlooked. Our study ﬁndings are in line, however, with
recent European and US-based evidence.16–18
Strengths and limitations
Our study has several important strengths including prospective
design, while cases and control groups were selected from the
same population and information was collected in the same
manner; thus, selection and information bias is likely to be
minimal. Patients were included only if they had been registered
at the practice for 12 months or more, ensuring accurate date of
diagnosis and reliable clinical and therapy data. Our data source
has a high level of ethnicity recording and reﬂects patients from
a very wide range of socioeconomic backgrounds, promoting
the generalisability of the ﬁndings. However, as with any obser-
vational data there are important limitations that need acknowl-
edgement. We drew on the READ code classiﬁcation, used in
UK primary care to identify chronic inﬂammatory disease diag-
nosis, comorbidities, treatment and risk factor management. We
acknowledge that alternative codes might be proposed. Only
data from primary care setting were available and no data from
specialist clinics were available, which could impact the identiﬁ-
cation of patients and CV risk factors assessment into our study.
Confounding is also common in observational studies and there
may be other relevant factors that were unavailable to us. Also,
primary care practitioners may record some of the CV risk
factors data in a textual format, which was not available to us. It
is also possible that primary care practitioners may not record
CV risk factors information collected previously if there was no
apparent change in these factors, particularly with respect to
smoking and BMI. While this suggestion may partially explain
the low rates of measurement for some CV risk factors, it is
unlikely to be responsible for the low rates observed among SBP
and cholesterol levels. The poor predictive value of existing risk
scores may also discourage their use in inﬂammatory patients.
CONCLUSION
On the positive side, our study ﬁndings document greater rates
of SBP, BMI and smoking assessment among patients with RA
and IBD compared with their matched controls. Unfortunately,
Table 3 Conditional Poisson regression analysis for differences in CV risk factor measurement among patients with RA and IBD compared with
their matched controls
RA N (%) IBD N (%)
Time period
1 year before index date 1.22 (1.11 to 1.33) 3171 (59) 1.33 (1.23 to 1.44) 4840 (53)
1 year after index date 1.25 (1.12 to 1.35) 3200 (59) 1.26 (1.16 to 1.38) 4428 (48)
Within 5 years from index date 1.08 (1.04 to 1.14) 3941 (73) 1.10 (1.05 to 1.15) 5473 (60)
The incidence rate ratios were adjusted for ethnicity, age, gender and deprivation.
CV, cardiovascular; IBD, inflammatory bowel disease; N, number; RA, rheumatoid arthritis.
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this ﬁnding was outdone by the substantively low rates of CV
risk factors measurement and treatment among a group of
patients known to be at heightened risk of future CVD events.
Of particular concern was that a CVD risk score calculation was
possible for only 2% of the patients with RA and IBD within
the ﬁrst 12 months following disease diagnosis. Even when con-
sidered individually and over a 5-year period, less than half of
patients with RA and IBD had their CV risk factors assessed.
Our study ﬁndings emphasise the need for initiatives to increase
primary care practitioners’ awareness about the importance for
recording data on CV risk factors among patients with RA and
IBD. Given the limited feasibility for this information to be col-
lected within the constraints of a time-limited consultation,
alternative strategies for CV risk factors data collection need to
be tested (ie, patient-reported data, nurse-based assessment,
improved primary–secondary care communication).
Key messages
What is already known on this subject?
Patients diagnosed with chronic inﬂammatory disorders are at
increased risk of cardiovascular disease (CVD) events. Existing
evidence documented poor CV risk factors assessment and
management in rheumatology clinics. Less evidence is available,
however, from primary care practices and across different
inﬂammatory disorders.
What might this study add?
CV risk assessment and management in primary care practices
is very low. Patients with inﬂammatory bowel disease (IBD) have
lower rates of CV risk factors assessment and management
comparing to their rheumatoid arthritis (RA) counterparts. Only
a small minority of patients with RA and IBD are assessed for
the presence of all four CV risk factors to enable calculation of
a CV risk score
How might this impact on clinical practice?
Currently, only a minority of patients with RA and IBD are
assessed for the presence of CV risk factors in primary care
settings. Primary care practitioners should be encouraged and
supported to screen for CV risk among patients with RA and
IBD.
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